retatrutide diabetes type 2 🩺 in diabetes: TRANSCEND-T2D-1 Phase 3 results → HbA1c ↓2.0% + weight ↓16.8% at 40 weeks. A triple agonist that tackles both glycemia and obesity simultaneously. 📊💊 Ref: Lilly 💊🔥 Retatrutide: The Most Powerful

So far, studies have reported: Phase 2 (48 weeks): up to 24.2% average weight loss Phase 3 TRIUMPH-4 topline (68 weeks): 28.7% average weight loss (press release) What that looks like: If you start at 100 kg : 24.2% 24 kg average loss 28.7% 29 kg average loss Side effects and safety signals (what we know so far) Phase 2 (peer-reviewed) In the phase 2 trial, the most common adverse events were gastrointestinal and dose-related, typically mild to moderate

S.GouldE.OrchinikM.WeilandN

Noom Microdose GLP-1 Rx Program GLP-1 treatment paired with Noom behavior change Program 17 pounds in 60 days 1 Low-dose GLP-1 designed to reduce observable side effects All-inclusive pricing: clinical care and medication Full access to Nooms program , focused on behavioral change and psychology for lasting results

Understanding that GLP-1 medications take time to reach therapeutic levels prevents discouragement during the early titration phase